Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNP-104 in Primary Biliary Cholangitis
NCT05104853Phase 2Completed
- Sponsor
- COUR Pharmaceuticals
- Start
- Jan 2022
- Primary completion
- Jan 2026
- Modality
- Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of CNP-104 in primary biliary cholangitis (PBC), sponsored by COUR Pharmaceuticals. Started Jan 2022; status: completed.
02
Drugs
CNP-104
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT05104853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05104853.